News of Note—Clementia IPO; Eloxx series C; Collidion-Plex stake

Investment is the name of the game in today's news of note.

> Following on from a spate of biotech public offerings in recent months, ultrarare bone disease biotech Clementia has priced its IPO at the high end at $15 a pop, bringing in a chunky $120 million. Insiders bought about a quarter of the shares. The Canadian biotech plans to use the cash to bankroll late-phase trials of an oral retinoic acid receptor gamma agonist it licensed from Roche. Release

> Eloxx Pharmaceuticals has gained an additional $8 million investment by LSP, a healthcare investor, boosting its series C to $38 million. The funds will be put toward its work on genetic diseases caused by nonsense mutations. Statement

> And it's money news galore as Collidion and Plex Pharmaceuticals have penned a new deal that sees Collidion get its hands on an 80% equity stake in Plex in exchange for an “undisclosed amount of cash and contributing a novel drug asset under development.” The pact also sees Collidion give “management and operational support” as Plex works on meds for Parkinson's disease, glioblastoma and cataracts. Release


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

Suggested Articles

The FDA approved the first spinal tether to correct the most common form of scoliosis—a ropelike implant that pulls the vertebrae into shape.

Agilent launched a new analyzer for research that observes cell behavior in real time while also collecting biosensor information.

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy.